Close Menu

People in the News

Jul 01, 2019

Keith Kennedy

Veracyte has appointed Keith Kennedy as chief operating officer. Prior to joining Veracyte, Kennedy served as executive leadership positions at MCG Capital, Arlington Capital Partners, and GE Capital over the past 20 years.

Jun 28, 2019

Eugene Durenard, Ted Murphy

Co-Diagnostics have appointed Eugene Durenard and Ted Murphy to its board of directors, and will serve on the board's compensation and corporate governance/nomination committees and audit committees as independent directors. The two new members will be replacing Frank Kiesnar, who resigned as director of the firm, and Edward Borkowski, who retired as a director of the firm.

Durenard has been founder and CEO of Hyperbolic Holdings since 2018, co-founder and chief innovation officer of Healthcare Impact Holdings since May 2018, co-founder and trustee of Healthcare Impact Foundation since 2017, co-founder of Global Better Health since December 2018, as well as advisor and managing director of the Stetson Family Office since September 2016.

Murphy serves on the board of directors of three Canadian publicly reporting companies, as well as a senior partner in a private investment firm since 1999.

Jun 27, 2019

Thomas West

Hologic announced that Thomas West, its diagnostics division president, resigned effective July 1. In a filing with the US Securities and Exchange Commission, the firm said he is leaving Hologic to assume the role of CEO at another publicly traded company.

Jun 26, 2019

Margot Schoenborn

OmniSeq announced today that it has appointed Margot Schoenborn to succeed Mark Gardner as the firm's CEO. Schoenborn joined the firm as senior VP, general counsel and corporate secretary in 2015 and was later appointed chief administrative officer. Prior to OmniSeq, Schoenborn served as deputy general counsel at the Roswell Park Comprehensive Cancer Center. Before that, she served as a special assistant attorney general for New York and as a assistant US attorney for the Eastern District of New York. 

Jun 26, 2019

Stefano Giolito

RevoluGen has appointed Stefano Giolito as chief marketing officer. With more than 20 years of marketing and research and development experience, Giolito previously served as marketing global VP at Unilever. 

Jun 26, 2019

Katie Breitenbach and Viktor Novy

CureMatch said today that it has hired Katie Breitenbach as chief financial officer and Viktor Novy as chief technical officer. Breitenbach brings experience with venture-backed startups and preparation for initial public offerings the software and cloud-services industries. Novy is a former IT director at Human Longevity. CureMatch is a San Diego-based startup that provides artificial intelligence-driven oncology treatment analysis services, including clinical decision support.

Jun 25, 2019

Rupert Vessey

Bio-Techne appointed Rupert Vessey as an independent director to its board of directors, bringing the total number of board members to nine.

He is the president of global research and early development at Celgene. Before joining Celgene, Vessey held various R&D senior management positions at Merck. Previously, he worked in drug discovery, experimental medicine, and early clinical development at GlaxoSmithKline.

Jun 25, 2019

Eric Rasmussen, Bryan Baldasare

Meridian Bioscience has announced that Eric Rasmussen has resigned his position as executive vice president and CFO effective June 28, 2019 in order to pursue other opportunities. Meridian has appointed Bryan Baldasare, currently its senior vice president, corporate controller, treasurer, and chief accounting officer, to serve as interim CFO.

Jun 21, 2019

Puneet Sarin

BD has appointed Puneet Sarin the worldwide president of BD Biosciences. He will be responsible for driving the global strategic, operational, and commercial performance across BD Biosciences. Sarin was previously senior vice president and general manger of the chemistry and immunoassay business unit at Beckman Coulter. Prior to Beckman Coulter, he was at GE. 
Jun 21, 2019

Steven Daniel

Cofactor Genomics has appointed Steven Daniel as VP of business development. Daniel previously served as senior director of applied sciences and business development at ArcherDx. Prior to ArcherDx, he was VP of sales at Genos/Nantomics, senior director of pharma business development at Adaptive Biotechnologies, and held commercial roles at Life Technologies, AltheaDX, Metabolon, and Affymetrix.

Jun 19, 2019

Donald Berry

OTraces has announced that Donald Berry has joined its scientific advisory board. Berry is professor of biostatistics and founding chair of quantitative sciences at the University of Texas MD Anderson Cancer Center, bringing extensive cancer research and policy experience including work with the National Cancer Institute PDQ Screening and Prevention Committee. He has also worked closely with the FDA Center for Devices and Radiological Health, helping to set rigorous scientific and quality standards.

Jun 19, 2019

Cengiz Yakicier

UAE-based Agiomix has appointed Cengiz Yakicier to its board as a medical director. Cengiz currently serves as the director of molecular pathology laboratory at Acibadem in Istanbul, Turkey.

Jun 18, 2019

Don Enns

Microbiome Insights has appointed Don Enns as an independent member of its board of directors. Enns currently serves as VP and head of global drug delivery at Evonik Industries, joining the firm in 2016 with its acquisition of Transferra Nanoscience, where he served as president and CEO. Prior to Transferra, Enns was president and CEO at Cantest before the firm was acquired by Maxxam Analytics in 2009.

Jun 18, 2019

Francois Martelet

Novigenix has appointed Francois Martelet as a non-executive director. Martelet recently retired as CEO at NetScientific. He was also chairman of several companies, including Vortex BioSciences, Wanda, Glycotest, and ProAxsis. Prior to that, Martelet was CEO at Topotarget and held senior commercial roles at Novartis Pharma and Merck.

Jun 17, 2019

Stefan Timmerman

Stefan Timmerman has been appointed CFO of Dutch transplantation and companion diagnostics firm Genome Diagnostics. Currently group controller of private equity firm Broadview Holding, Timmerman was previously controller at SNS bank. Before that, he held the same postition at ASN bank. 

Jun 14, 2019

Leena Das-Young

Guardant health said that Leena Das-Young is leaving her position as chief LUNAR officer and general manager at the company for personal reasons. She will continue her service with the firm through June 18, 2019. In connection with her departure, and in exchange for a customary release of claims, Das-Young will be entitled to certain benefits under the company’s executive severance plan, as well as the retention of certain relocation benefits previously provided to her.

Jun 14, 2019

Amelia Warner

Predictive Oncology has appointed Amelia Warner as the interim chief operating officer of its Helomics subsidiary. Prior to joining Helomics, Warner founded Global Specimens Solutions in 2013. Before GSS, Warner served as CEO for Gentris. She has also served as head of clinical pharmacogenomics and clinical specimen management for Merck. In addition, she has served as chair of the Industry Pharmacogenomics Working Group. 

Jun 13, 2019

Bartu Ahiska

Oxford Biodynamics has appointed Bartu Ahiska as senior vice president (commercial) to spearhead commercialization of the company's EpiSwitch technology platform. Ahisku joins OBD from the Knight Cancer Early Detection Advanced Research Center at Oregon Health & Science University in Portland, where he has been the manager of innovation, IP, and and commercialization since 2016. He was a cofounder and remains a non-executive director of Trogenex in San Diego, and was COO and CEO of cloud-computing company Approxy before its acquisition by Numecent.

Jun 12, 2019

Kristiina Vuori

Bionano Genomics has appointed Kristiina Vuori to its board of directors. Vuori is president and a board member of the Sanford Burnham Prebys Medical Discovery Institute (SBP.) She also serves as a professor at SBP's National Cancer Institute-designated Cancer Center. She holds an MD and PhD from Finland's University of Oulu. Her research has helped delineate molecular pathways that regulate cancer cell survival, motility, metastasis, and drug responsiveness. Her molecular characterization of prolyl hydroxylase helped to enable the formation of FibroGen. 

Jun 11, 2019

Thomas Schinecker, Barbara Schädler, Michael Heuer, Stephan Feldhaus, Peter Voser

Thomas Schinecker has been appointed as CEO of Roche Diagnostics and a member of the firm's corporate executive committee, effective August 1. He will succeed Michael Heuer, who is retiring at the end of July. Schinecker is currently head of Centralized and Point of Care Solutions at Roche Diagnostics. Previously, he was general manager for Roche Diagnostics Germany, and before that, he held various management positions in marketing and sales as well as product development at Roche Diagnostics. He holds a PhD in molecular biology from New York University.

Barbara Schädler will become head of group communications and a member of Roche's enlarged Corporate Executive Committee, effective October 1. She will succeed Stephan Feldhaus, who will leave Roche at the end of September. Schädler is currently head of communications and public affairs at E.ON. Previously, she held communications manager positions at Lufthansa, SAP, and the German Federal Ministry of Finance. She holds a master's degree in economics from the University of Mainz.

Peter Voser will step down from the board of directors of Roche at the end of June due to his additional role as interim CEO of ABB.

Jun 11, 2019

Gail Marcus

Binx Health has appointed Gail Marcus to its board of directors. Marcus has held executive positions in a number of healthcare sectors, including services, diagnostics, healthcare provision, and managed care. She held leadership positions at United Healthcare, Cigna, and private equity-backed diagnostic organizations; has an academic appointment at Massachusetts College of Pharmacy and Health Sciences; and serves on the boards of Natera, Cambridge Epigenetix, and Triple S Management, a Blue Cross Blue Shield affiliate in Puerto Rico.

Jun 07, 2019

Hans Bishop, Jennifer Cook, Joshua Ofman, Maykin Ho, Renée Galá

Grail has appointed Hans Bishop as the firm's CEO. He succeeds Jennifer Cook, who has stepped down from the position for family health reasons. Bishop has served on the firm's board of directors since 2018 and will continue serving as its director. Bishop will also continue serving as executive chair of the Sana board of directors, as well as director of Celgene, Agilent Technologies, and Lyell Immunopharma. Bishop founded Juno Therapeutics in 2013 and served as the firm's president and CEO until it was acquired by Celgene in 2018. Prior to Juno, he served as executive in residence at Warburg Pincus. Before Warburg, Bishop served as executive VP and chief operating officer for Dendreon. Prior to Dendreon, he served as president of specialty medicine at Bayer Healthcare, senior VP of global commercial operations at Chiron, and VP and general manager of European Biopharmaceuticals.

Grail has also appointed Joshua Ofman as its chief of corporate strategy and external affairs. Prior to Grail, Ofman most recently served as senior VP of global health policy at Amgen. Before joining Amgen in 2003, Ofman was a member of the academic faculty at the University of California, Los Angeles School of Medicine, Cedars-Sinai Medicine Center. Ofman also served as senior VP of Zynx Health.

Grail has also appointed Maykin Ho to its board as an independent director. Ho is currently a venture partner of Qiming Venture Partners and a member of the Biotech Advisory Panel of the Stock Exchange of Hong Kong. She serves on the board of directors for FibroGen, Agios Pharmaceuticals, Parexel International, the Aaron Diamond AIDS Research Center, and the Institute for Protein Innovation. Ho is a retired partner of the Goldman Sachs Group, where she served as senior biotechnology analyst, co-head of healthcare for global investment research, and advisory director for healthcare investment banking. Before Goldman Sachs, Ho held various managerial positions at DuPont-Merck Pharmaceuticals and DuPont de Nemours & Company.

Grail also announced that Renée Galá has stepped down as the firm's CFO.

Jun 06, 2019

Eric d'Esparbes

Progenity has hired Eric d'Esparbes as its senior VP and CFO. Prior to Progenity, d'Esparbes served as CFO and interim principal executive officer at Innoviva. Before Innoviva, he held roles as CFO at Joule Unlimited, VP of finance at AEI, and CFO for Meiya Power Company. 

Jun 06, 2019

Ronald Andrews

OncoCyte has appointed Ronald Andrews as its CEO, effective July 1. In addition to serving as a board member at OncoCyte, Andrews has over 30 years of experience in the clinical and molecular diagnostics field. OncoCyte's current CEO, William Annett, will remain with the company in an advisory role.

Prior to joining the firm, Andrews was the founder and principal of the Bethesda Group. Before Bethesda, he served as Thermo Fisher Scientific's genetic science division president, where he oversaw the integration of Life Technologies' genetic platform. He also served as president of Life Tech's Medical Science Venture. Before joining Life Tech, Andrews acted as CEO at Clarient (formerly ChromaVision Medical Systems), which was sold to GE Healthcare in 2010. He subsequently served as GE Molecular Diagnostics' CEO until 2011. Andrews also held various senior executive roles at Roche Diagnostics from 2000 to 2004. Andrews served as VP of marketing at Immucor from 1995 to 2000. Prior to Immucor, Andrews spent about 10 years in management positions at Abbott Diagnostics.

Jun 04, 2019

Andrew Quong

Andrew Quong has joined Fluidigm as the company's first-ever chief science officer. Quong was most recently director of strategic scientific initiatives and partnerships at the Frederick National Laboratory for Cancer Research, a National Cancer Institute-sponsored center. Prior to this, Quong was a faculty member in the Department of Cancer Biology at Thomas Jefferson University and the Department of Oncology at Georgetown University. Quong completed his postdoc at the Naval Research Laboratory as a National Research Council Fellow, and received his PhD in physics from the University of California, Irvine.

Pages

Retraction Watch reports that a paper was pulled because it refers to a gene that doesn't exist in mice.

Researchers were able to generate fertilized northern white rhinoceros eggs, according to Mashable.

Former Orig3n employees raise concerns about its testing at Bloomberg Businessweek.

In PLOS this week: microRNA expression changes in hepatocellular carcinoma, real-time PCR-based approach for diagnosing schistosomiasis, and more.